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Abstract: Changes in modern dietary habits such as consumption of Western-type diets affect
physiology on several levels, including metabolism and inflammation. It is currently unclear
whether changes in systemic metabolism due to dietary interventions are long-lasting and affect acute
inflammatory processes. Here, we investigated how high-fat diet (HFD) feeding altered systemic
metabolism and the metabolomic response to inflammatory stimuli. We conducted metabolomic
profiling of sera collected from Ldlr−/− mice on either regular chow diet (CD) or HFD, and after an
additional low-dose lipopolysaccharide (LPS) challenge. HFD feeding, as well as LPS treatment,
elicited pronounced metabolic changes. HFD qualitatively altered the systemic metabolic response
to LPS; particularly, serum concentrations of fatty acids and their metabolites varied between
LPS-challenged mice on HFD or CD, respectively. To investigate whether systemic metabolic changes
were sustained long-term, mice fed HFD were shifted back to CD after four weeks (HFD > CD).
When shifted back to CD, serum metabolites returned to baseline levels, and so did the response to
LPS. Our results imply that systemic metabolism rapidly adapts to dietary changes. The profound
systemic metabolic rewiring observed in response to diet might affect immune cell reprogramming
and inflammatory responses.
Keywords: western-type diets; lipopolysaccharide (LPS); systemic metabolism; systemic
inflammation; metabolomic profiling; long-term metabolic rewiring
1. Introduction
The prevalence of obesity and associated immuno-metabolic diseases has reached pandemic
proportions in modern Western societies. Permanent overnutrition of high-calorie convenience
products, a sedentary lifestyle, alcohol abuse, stress, lack of sleep and direct exposure to environmental
biotoxins, actively contribute to developing non-communicable lifestyle diseases (NCD). NCDs are
among the most common diseases and include obesity, type 2 diabetes mellitus, liver steatosis,
cardiovascular diseases, as well as neurodegenerative disorders, and certain types of cancer [1,2].
The World Health Organization now recognizes obesity as a global pandemic. Worldwide, the number
of obese children and adults has tripled between 1975 and 2016 [2]. In 2025, about 30% of the US
population will have type 2 diabetes, and 50% will be obese [3].
Several studies have shown that the permanent consumption of unhealthy convenience products
adversely impacts microbial resilience in the intestine. The intestinal tract is a complex system requiring
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continuous barrier integrity and regulatory mechanisms to maintain host–microbe interactions and,
consequently, immune-tissue homeostasis [4]. The human microbiome shows a high biodiversity in
the healthy state and is mainly characterized by the following microbiota: Bacteroidetes (Prevotella),
Firmicutes (Ruminococcus, Roseburia), Actinobacteria, Proteobacteria and Verrucomicrobiota [5]. Symbiotic
and commensal microorganisms dominate over opportunistic pathobionts. They are responsible for
healthy mucus production, the maintenance of barrier integrity and immune tolerance.
However, the permanent consumption of unhealthy high-calorie convenience products is
associated with a reduction in microbial species diversity, an overgrowth of pathobionts, a disturbed
barrier integrity and the disruption of the microbial immune homeostasis [6]. Overall, the microbiome
represents the interface between host’s nutritional and inflammatory environment. Dietary dysbiosis
leads to the release of inflammatory mediators and pathogenic microbial metabolites into the
bloodstream [6]. These factors adversely affect systemic metabolism (diet-induced metabolic
endotoxemia) and physiological functions of many organs, including intestine, liver, pancreas,
bone marrow, spleen and brain [7–10]. Long-term, disturbed immuno-metabolic processes lead to
disturbances in circulating levels of specific lipid and amino acid classes and cholesterol and trigger
inflammatory processes in NCDs [11]. We have recently shown in a mouse model of atherosclerosis
that feeding a high fat and high cholesterol Western diet (HFD) triggers long-term (epi-)genetic innate
immune cell reprogramming, a process known as “trained immunity” [12–14]. Four weeks of HFD
feeding induced systemic inflammation that subsided after shifting mice to control chow diet (CD).
Additionally, HFD triggered a proliferative hematopoietic cell expansion associated with functionally
reprogrammed myeloid precursors in the bone marrow compartment. Of note, these responses were
maintained over prolonged times even when reversing the diet from HFD to CD, indicating that
nutritional composition can induce cellular reprogramming [14]. Questions such as triggers (microbial
metabolic products), the duration, the specificity and reversibility of innate immune training in the
context of diet feeding still have to be answered. Moreover, it is currently unknown if changes in
systemic metabolism due to dietary interventions are long-lasting and how they likely affect acute
inflammatory processes, as well as sustained cellular reprogramming.
Recent studies have accentuated the advances in high-throughput metabolomics analysis to
unravel the complexity and specificity of metabolic alterations in mouse and human blood and tissues
upon dietary intervention [15,16]. Indeed, metabolomics approaches are valuable in identifying
diet-related metabolic signatures, which reflect microbial changes, health status and pathophysiological
conditions [17–20]. In a recent paper, Cirulli and co-workers used non-targeted metabolomics
and whole-genome sequencing to identify metabolic and genetic signatures in diet-induced obesity.
They assessed that the metabolome captures clinically relevant obesity phenotypes and is a better health
predictor than genetic risk [21]. Piening and colleagues recently performed a controlled longitudinal
weight perturbation study combining multiple omics strategies during weight gain and weight loss in
humans. Overall, they observed strong omics signatures upon weight gain (inflammatory responses,
insulin resistance), which were partly reversed upon weight loss [22]. Overall, studies that monitor the
long-term effects of perturbances in metabolic homeostasis are rare.
Here, we examined systemic metabolic alterations in response to diet and lipopolysaccharide
(LPS) challenge. We used high-throughput metabolomics analysis to profile metabolome levels in
sera collected from Ldlr−/− mice fed either CD or HFD and after additional low-dose LPS challenge
before sacrifice. HFD feeding, as well as LPS treatment by themselves, triggered pronounced metabolic
changes. HFD qualitatively altered the systemic metabolic response to LPS, particularly dynamics
for fatty acids and fatty acid-derived bioactive molecules. To identify unique long-term systemic
metabolic signatures, mice were fed HFD for four weeks and subsequently reset to CD (HFD > CD).
Serum metabolites, being elevated upon HFD feeding, returned to baseline levels analyzed in CD-fed
mice. Similarly, metabolic profiling in CD_LPS- and HFD > CD_LPS-fed mice resembled each other.
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Overall, we were able to detect profound systemic metabolic rewiring in response to diet
and LPS challenge that might be involved in long-term pathophysiological processes and immune
cell reprogramming.
2. Results
2.1. LPS Exposure and HFD Feeding Elicit Distinct and Mutual Changes on Systemic Metabolism
This study’s overall goal was to determine whether Ldlr−/− mice respond differently to LPS
exposure when maintained on CD or HFD, respectively. Additionally, we aimed to study long-term
diet effects on systemic metabolism. Therefore, mice were fed either CD and HFD, respectively,
for four weeks or four weeks HFD followed by four weeks CD (analysis of long-term diet effects).
At the end of dietary intervention, mice received an intravenous low-dose LPS injection (Figure 1a).
Sera were collected and subjected to non-targeted unbiased metabolite profiling. A total number of
579 compounds of known identity were detected (Table S1). Pearson correlation analysis revealed
that samples segregated into two major groups based on dietary intervention regimen: Cluster one
comprised all HFD samples, and cluster two all CD and HFD > CD samples. Within the different diet
treatment groups (CD/HFD > CD), samples separated based on LPS treatment (Figure 1b). Hierarchical
clustering analysis confirmed the pronounced effect elicited by HFD feeding. As shown by correlation
analysis, CD and HFD > CD samples were highly similar. While these samples also clustered upon
additional LPS treatment, HFD samples did less so (Figure 1c). Metabolite-wise hierarchical clustering
segregated the dataset into two major clusters, of which cluster one comprised metabolites that
were most abundant in the CD and HFD > CD groups, while the second cluster (2–5) comprised
metabolites particularly abundant in the HFD and LPS-treated groups. The latter further segregated
into sub-clusters with metabolites that were specifically increased upon LPS (3), HFD (4), and both
LPS and HFD (5) treatment (Figure 1c). These results indicate that HFD feeding and LPS treatment
elicit distinct and mutual changes in the serum metabolome. We next aimed to identify metabolites
that were significantly altered between the different treatment groups. We identified 112 significantly
altered metabolites for the CD_LPS group, 177 for the HFD and 184 for the HFD_LPS group, compared
to the CD group (Figure 1d). In accordance with the correlation and hierarchical clustering analysis,
the largest overlap amongst the former three groups was observed between the HFD and HFD_LPS
treatment groups (Figure 1d). A considerably smaller overlap was shown between the CD_LPS and
HFD, and the CD_LPS and HFD_LPS groups, respectively (Figure 1d).
2.2. LPS Challenge Specifically Increases Systemic Protein and Amino Acid Catabolism
We next analyzed changes in the LPS- and HFD-challenged metabolomes in further detail.
The CD_LPS group exhibited 51 upregulated and 61 downregulated metabolites compared to the
CD-feeding group (Figure 2a,b). N-acetyl N-Acetyl-1-methylhistidine, 1-docosahexaenoylglycerol,
C-glycosyltryptophan and N-acetyl-aspartyl-glutamate were among the most significantly altered
metabolites in the CD_LPS treatment group (Figure 2c). The induction of lipolysis has been well
described in the context of sepsis [23]. Indeed, almost 50% of LPS-modified serum metabolites
belonged to lipid classes (Figure 2b). In addition to 1-docosahexaenoylglycerol, a number of other
monoacylglycerol and lysolipids were upregulated in the CD_LPS treatment group (Table S2), and so
were several fatty acids (Figure 2d). Mobilization of fatty acids and related lipid metabolites seemed to
be limited to distinct fatty acid classes. LPS almost exclusively increased abundances of polyunsaturated
fatty acids such asω-3 andω-6 fatty acids. With the exception of myristoleate, no mono- or unsaturated
fatty acids were mobilized in response to LPS challenge (Figure 2d). Furthermore, we identified several
peptides and compounds related to amino acid metabolism being up- or downregulated upon LPS
challenge. This is in accordance with literature demonstrating that sepsis triggers changes in systemic
protein metabolism [23]. LPS led to a robust decline of a number of amino acids: Ornithine and
citrulline, metabolites of the urea cycle, which are known to eliminate amino acid-derived nitrogen in
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the liver, were downregulated, while the end product urea was increased in the LPS-challenged group
(Figure 2d). Guanidinoacetate, being synthesized in the kidney and serving together with ornithine as
precursor for the creatine biosynthesis, was decreased, while creatine was increased upon LPS challenge
(Figure 2d). Nucleotides were also prominently represented among the upregulated metabolites,
and so were nicotinamide and metabolites thereof (Figure 2d). Overall, these results suggest that LPS
challenge in CD-fed Ldlr−/− mice increases systemic protein and amino acid catabolism.
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correlation analysis of all samples presented in the dataset. Correlation scores were color-scaled; (c) 
Metabolite and sample-wise hierarchical clustering analysis of the entire dataset; (d) Venn diagram 
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2.3. HFD Feeding Is Strongly Impacting Lipid Metabolites
HFD feeding altered a total of 177 biochemicals, of which 95 were up- and 82 were downregulated.
(Figure 3a,b). Upon HFD feeding, a high number of lipids and lipid metabolites were significantly
altered, particularly in the upregulated fraction. Cholesterol was highly enriched, so was mead acid,
aω-9 fatty acid that is produced from oleic acid in response to deprivation of essential fatty acids [24].
Additionally, sphingomyelin (SM) (d18:2/14:0, d18:1/14:1) and further sphingolipids were highly
enriched upon HFD feeding (Table S2). Of note, linoleate (18:2) and phosphatidylcholine (PC) 18:2/18:3
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were among the most significantly downregulated molecules. When analyzing all differentially
regulated fatty acids, we observed that, with the exception of mead acid andω-6 docosapentaenoate
(22:5n6), only saturated and monounsaturated fatty acids increased upon HFD feeding. In contrast,
several essential polyunsaturated fatty acids were markedly decreased. In particular,ω-3 fatty acid
species were strongly affected (Figure 3d). Similarly, we found several phospholipid and plasminogen
species, encompassing linoleate (18:2), being downregulated, while a higher number of palmitate
(16:0), stearate (18:0) and oleate (18:1)-containing lipids was elevated in the HFD feeding group.
We observed a similar regulation pattern for other lipid metabolites, such as monoacylglycerols
and lysolipids (Table S2). Besides lipid-related molecules, numerous amino acid metabolites and
diet- and microbiome-derived xenobiotics were decreased upon HFD feeding (Figure 3b). The most
strongly downregulated amino acid metabolite was indoleproprionate, a tryptophan derivate that
is produced by the gut microbiota [25], supporting intestinal barrier integrity [26]. Likewise, several
other microbiome-derived circulating metabolites, important in maintaining the microbiome-immune
homeostasis, were decreased upon HFD feeding. Moreover, and just like LPS challenge, HFD feeding
altered levels of proteinogenic amino acids and related compounds. In particular, branched-chain
amino acids and related metabolites were altered in mice fed a HFD, while LPS challenge affected
primarily global amino acid catabolism (Figure 3d).
2.4. Effects of LPS Exposure and HFD Feeding on Systemic Metabolism Are Not of Long-Lasting Nature
Global unbiased analysis of the dataset revealed that a switch of HFD-fed Ldlr−/− mice back to
CD restored their metabolome, meaning that HFD-induced metabolic alterations returned to baseline,
resembling the metabolome of CD-fed mice (Figure 1b,c). Indeed, we observed that all metabolites,
being up- or downregulated, respectively, in the HFD-fed group, returned to baseline levels described
in the CD-fed group, in the HFD > CD group (Figure 4a). We have previously observed a state of
enhanced LPS-responsiveness in bone marrow myeloid progenitor cells as well as in tissue-resident
macrophages after switching mice from HFD back to CD [14]. To assess whether the same applies to
systemic metabolism, we analyzed and compared the LPS-challenged metabolome in CD- and HFD >
CD-fed groups. Pearson correlation analysis and hierarchical clustering have demonstrated that HFD
> CD feeding did not drastically alter systemic metabolic response upon additional LPS challenge
(Figure 1b,c). Likewise, we did not observe significant differences in the abundance of LPS-altered
metabolites (either up- or downregulated) in the HFD > CD- compared to the CD-fed group (Figure 4b).
Metabolites 2020, 10, 336 7 of 20
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Figure 3. HFD feeding is strongly impacting lipid metabolites. (a) Volcano plot indicating changes
in metabolite abundances between the HFD- and the CD-fed groups (q-value < 0.05 is considered
significant). −log10 and log10 q-values and fold changes, respectively, are depicted; (b) Pie charts
indicating numbers of altered metabolites in the HFD-fed group compared to the CD-fed group
based on their biological classification; (c) Abundances of significantly upregulated metabolites in the
HFD-fed group. Individual values, means and SEM are presented; (d) Representation of significantly
up- or downregulated metabolites in the HFD-fed group. Metabolite abundances were z-transformed
and scaled.
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Figure 4. The effects of LPS exposure and HFD feeding on systemic etabolism are not of a long-lasting
nature. (a) Abundances of metabolites upregulated in the CD-, the HFD- or the HFD > CD-fed groups.
Means of individual metabolites are presented; (b) Abundances of metabolites upregulated by LPS
challenge in the CD-fed group (CD_LPS) and the HFD > CD-fed group (HFD > CD_LPS). Means of
individual metabolites are presented.
2.5. LPS Treat ent and F Feeding ave Synergistic Effects on Syste ic etabolis
To investigate whether the combined treatment of HFD feeding and LPS challenge altered systemic
metabolis , we co pared systemic metabolite abundances between mice fed CD or HFD diet and
additional LPS challenge. We identified 74 significantly altered metabolites, most of them being lipids
(Figure 5a,b). Additionally, amino acid metabolites and xenobiotics were altered (Figure 5b). The most
dynamically altered metabolites that were already modified by HFD feeding were the following:
mead acid, sphingomyelins, BCAA metabolites, essential fatty acids and metabolites thereof such as 9,
10-DiHOME and 12, 13-DiHOME, which are produced from linoleic acid (Figure 5c,d and Table S2).
Notably, the essentialω-3 fatty acids stearidonate, eicosapentaenoate and linoleate were among the
most significantly downregulated molecules in the HFD_LPS group (Figure 5d). LPS treatment did not
significantly alter systemic levels of these metabolites, yet tended to increase them.
obilization of fatty acids from adipose tissue is a metabolic hallmark of inflammation. Likewise,
we also found several fatty acids increased upon LPS challenge (Figure 2d). Here, we analyzed
whether these metabolites were also mobilized upon LPS challenge in HFD-fed mice. Dihomo-linoleate
(20:2n6), dihomo-linolenate (20:3n3 or n6), docosadienoate (22:2n6) were mobilized to a similar degree
in the HFD_LPS-treated group; however, levels of the ω-3 fatty acids docosahexaenoate (22:6n3),
docosapentaenoate (22:5n3), docosatrienoate (22:3n3), did not increase upon LPS challenge in HFD-fed
mice but were significantly reduced compared to the CD_LPS-treated mice (Figure 6a and Table S2).
Next, we analyzed how additional LPS challenge altered serum concentrations of fatty acids (mostly
unsaturated and monounsaturated fatty acids) being elevated upon HFD feeding (Figure 3d). None of
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the HFD-induced saturated fatty acids further increased upon LPS challenge, though circulating levels
of laurate (12:0), mead acid (20:3n9), pentadecanoate (15:0), 10-nonadecenoate (19:1n9) and myristoleate
(14:1n5) were significantly elevated compared to levels in the CD_LPS group (Figures 5c and 6b,c and
Table S2). For several metabolites and metabolite classes, synergistic effects between HFD feeding and
LPS challenge were observed. For example, stearoryl ethanolamide, an endocannabinoid, as well as
the dicarboxillic acid tetradecanedioate, were among the most dynamically altered metabolites when
comparing the CD_LPS- and HFD_LPS-treated groups. Moreover, when comparing all significantly
altered endocannabinoids between the CD-, CD_LPS-, HFD- and HFD_LPS-treated groups, we found
that stearoyl ethanolamide, palmitoyl ethanolamide, N-oleoyltaurine oleoyl ethanolamide were
markedly elevated in the CD_LPS-treated group (Figure 6d and Table S2). N-stearoyltaurine and
N-palmitoyltaurine were additionally increased in the HFD_LPS-treated group (Figure 6d and Table S2).
Overall, there was a clear trend for all six metabolites being increased in the HFD_LPS compared
to the CD_LPS-treated group. (Table S2). Elevated acylcarnitine serum levels have been detected in
sepsis and obesity and are thought to occur as a result of defects in β-oxidation [27,28]. In our diet
model, we also identified numerous acylcarnitine species being elevated in the CD_LPS-, as well as the
HFD-treated groups (Figure 6e and Table S2). Additionally, we identified significantly elevated levels
of dicarboxilic acids and corresponding metabolites (Figure 6e and Table S2). Dicarboxilic acids are
products of fatty acidω-oxidation, occurring when β-oxidation is impaired [29].
Metabolites 2020, 10, 336 10 of 20
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Figure 6. Synergistic effects of LPS treatment and HFD feeding on specific metabolite classes.
(a–e) Abundances of (a) Endocannabinoids; (b) LPS-upregulated fatty acids; (c) HFD-upregulated
unsaturated fatty acids; (d) HFD-upregulated saturated fatty acids in the CD-, CD_LPS-, HFD- and
HFD_LPS-treated groups. Means of individual metabolites are presented; (e) Abundances of
upregulated acylcarnitines and dicarboxilic acids. Means and SEM are presented.
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3. Discussion
Consumption of Western-type diets, as well as inflammatory processes, goes along with
profound changes in systemic metabolism, which are long-term associated with the development
of non-communicable metabolic diseases [30]. As such, diet-induced disturbances of the
immuno-metabolic balance lead to several chronic metabolic disorders, including obesity, type 2
diabetes, atherosclerosis and cardiovascular diseases, certain neurodegenerative disorders, as well as
certain types of cancer [11,21]. In the present study, we aimed to investigate how changing from a healthy
plant-based balanced diet to a Western-type diet, highly enriched in animal fats and refined sugars,
adversely affects global metabolism and systemic metabolic responses to LPS challenge. Particularly,
we were interested in analyzing diet-dependent metabolic alterations, potentially affecting inflammatory
processes and systemic immune responses in the early phase of atherosclerosis development (4 weeks
post-diet feeding). Western diet-related increased circulating LDL cholesterol levels have been linked
mechanistically and genetically to inflammatory processes and a heightened risk of developing
atherosclerosis [31]. Hence, the high-fat diet chosen in this study did not only contain more fat but also
varied in the content of cholesterol and the quality composition of the fat source. The influence of HFD
was reflected in global metabolic changes, most widely seen in the altered abundance of free fatty acids
and associated metabolites. Beyond this, we analysed LPS-distinct and overlapping global metabolic
signatures in Ldlr−/− mice fed either CD or HFD and compared them to metabolic signatures observed
only in HFD-fed mice. Profound systemic metabolic rewiring in response to diet might be involved
in long-term immune cell reprogramming. We have previously investigated whether high fat/high
cholesterol diet feeding triggers trained immunity in the Ldlr−/− atherosclerosis mouse model [14].
We demonstrated that HFD feeding induced systemic inflammation, shown by elevated circulating
inflammatory cytokines, that subsided after shifting mice to control CD. Of note, HFD feeding induced
immune cell reprogramming that was maintained over prolonged times, even after reversing the
diet from HFD to CD. To identify the long-lasting nature of HFD feeding on systemic metabolism,
we compared metabolic signatures in CD-fed, HFD-fed and HFD > CD-fed mice and upon additional
LPS challenge. To our surprise, neither HFD > CD feeding nor HFD > CD_LPS treatment re-displayed
HFD-induced metabolic alterations. Levels of circulating metabolites were comparable in HFD > CD-
and CD-fed mice.
LPS treatment, the causative agent of sepsis, already evoked strong global metabolic rewiring in
CD-fed animals, as described previously [23]. Cytokines and hormones released throughout sepsis
induce lipolysis in adipose tissue, while β-oxidation decreases [23,32]. In addition, increased protein
catabolism and nitrogen loss, resulting from proteolysis in skeletal muscle and hepatic amino acid
metabolism and ureagenesis, have been observed [23,33]. Several studies addressed global changes in
the serum metabolome in the context of sepsis [27,34,35]. In our model, we applied a low LPS dose to
reflect a state of endotoxemia rather than septic shock. However, we also observed dynamic changes
in amino acid and lipid metabolism. In the clinical diagnostics, sepsis-induced lipolysis is routinely
assessed by measuring global free fatty acid or glycerol concentrations. In our study, we observed
that particularly essential polyunsaturated fatty acids were increased in serum by LPS treatment.
We also observed increased levels of N-Acetyl-Aspartyl-Glutamate (NAAG) in LPS-treated mice.
NAAG’s function as a neurotransmitter has been studied extensively. Recent research uncovered that
NAAG serves as a glutamate source for tumor and lymphoma cells [36]. While it is well appreciated
that amino acids and free fatty acids released during sepsis may serve as nutrients to immune cells,
the role of NAAG or the converting enzyme glutamate carboxypeptidase II has not been studied so far.
As expected, cholesterol was one of the metabolites highly enriched upon HFD feeding in our
systemic metabolomics analysis. Cholesterol is a well-known risk factor for atherosclerosis [37,38].
Several studies have shown that cholesterol from animal fats is one of the robust drivers of inflammation
in atherosclerosis [7,39,40]. HFD feeding also induced increases in fatty acid phospholipids and
phospholipid catabolites (e.g., monoacylglycerols, lysolipids and lysoplasmalogens).
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It is well appreciated that Westernized nutrition qualitatively and quantitatively alters the
intestinal microbial ecosystem, adversely promoting overgrowth of pathogenic strains and altering
microbial metabolism [19,41]. In eubiotic microbiomes, symbiotic and commensal microorganisms
dominate over opportunistic pathobionts. They are responsible for inhibiting the production of
endotoxins in the gut, as well as for maintaining intestinal epithelium homeostasis. Nutritional
dysbiosis leads to impaired barrier integrity, loss of local immune tissue homeostasis and to increased
levels of plasma endotoxins [42,43]. Here, we observed dynamic changes in serum concentrations of
microbiome-derived molecules. The amino acid metabolite indole-3-propionic acid (IPA), a tryptophan
derivate that is produced by the gut microbiota, was markedly reduced [25]. Zhao and colleagues
have recently shown that IPA inhibits microbial dysbiosis in rats fed HFD. Moreover, IPA induces the
expression of tight junction proteins, such as ZO-1 and Occludin, which are important in maintaining
barrier integrity, thus reducing plasma endotoxin levels. Additionally, IPA exhibited anti-inflammatory
abilities in reducing levels of inflammatory cytokines and repressing liver inflammation. Overall,
IPA’s protective role is associated with control of metabolic and inflammatory pathways within the
intestinal and hepatic microenvironment [26].
Several other aromatic amino acid metabolites, amongst others daidzein and other isoflavones,
being produced through the phenylpropanoid pathway and important in inhibiting intestinal
permeability and systemic immunity [25], were decreased in our diet feeding model. Previous
studies have shown that a small number of bacteria, including Clostridium sporogenes, a gut bacterium
from the phylum Firmicutes, are mainly responsible for metabolizing phenylalanine and tyrosine to
their corresponding propionic acid derivatives [25]. Overall, diet-related dysbiosis is associated with
imbalanced microbial metabolism, increased production of intestinal endotoxins, systemic metabolic
endotoxemia, and immune and metabolic system-linked diseases [42,43].
Of note, Cao and colleagues have recently examined the contribution of gut microbiota-diet
interactions to obesity [44]. Using a diet-induced obesity mouse model, they were able to show
that some mice were resistant to HFD-induced obesity. While performing 16S rRNA sequencing,
they found several microbial alterations potentially being associated with obesity resistance. Overall,
differences in gut microbial composition and function might be linked with differences in metabolism
and individual’s resistance to HFD-induced obesity. These results are of importance for future studies
when analyzing HFD-induced obesity both in human and mice.
Next to alterations in aromatic amino acids, HFD-fed mice also exhibited prominent alterations in
several classes of bioactive molecules that have been shown to affect immune processes. In particular,
monosaturated and saturated fatty acids (SFA) were highly abundant as a result of HFD feeding.
Fatty acids are an important energy source and are readily taken up and stored as triacylglycerides or
metabolized by immune cells upon activation [45]. It has been shown that fatty acids affect immune
cell homeostasis and function via their metabolism or engagement with specific membrane receptors.
Moreover, the fatty acid composition of membrane lipids influences the fluidity of membranes [46–49].
Otherwise, lipotoxicity, mitochondrial dysfunction and endoplasmatic reticulum stress, all being
observed in the context of metabolic diseases, are induced by saturated fatty acids, which are potent
drivers of inflammatory processes [47,50–52]. Of note, some of the detrimental effects of saturated fatty
acids are mitigated by desaturation or the presence of unsaturated fatty acids [50–52], highlighting the
importance of balanced dietary fats.
Moreover, HFD-fed mice showed significantly higher levels of several medium-chain fatty acids,
which are primarily oxidized in the liver [53] and are only poorly incorporated into cellular lipids
by non-adipocyte cells [54]. Yet, not much is known whether and how immune cells metabolize
medium-chain fatty acids or which pathways are engaged by exposure to them.
In contrast to an LPS challenge, significant decreases were observed in several polyunsaturated
fatty acids (PUFAs), particularly theω-3 variants in HFD-fed mice. ω-3 fatty acids are potent activators
of the G-protein-coupled receptor GPR120 [55] and affect systemic energy balance by triggering the
release of gut-derived hormones [55,56]. ω-3 Fatty acids are potent anti-inflammatory molecules that
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also directly act on immune cells and inhibit TLR signaling in macrophages and decrease the Th17/Treg
ratio [57,58]. Indeed, the application of ω-3 fatty acids ameliorates atherosclerosis and metabolic
disease progression [57,59].
Hence, upon HFD feeding itself, immune cell subsets are exposed to a vastly different mixture
of fatty acids. The synergistic effect of HFD feeding and LPS challenge additionally induces a
different global metabolic signature than the LPS challenge in CD-fed mice. Under inflammatory
conditions, immune cells employ fatty acids to synthesize lipid mediators such as the proinflammatory
prostaglandins and leukotrienes and the anti-inflammatory lipoxins, resolvins, maresins and protectins.
Prostaglandins, leukotrienes and lipoxins are all generated from arachidonic acid, a ω-6 fatty acid,
while resolvins, maresins and protectins are derived fromω-3 fatty acids [60–62]. ω-3 fatty acids and
their metabolites additionally exert anti-inflammatory effects by interfering with synthesis of ω-6 fatty
acid-derived lipid mediators [62]. Thus, in addition to its proinflammatory character, HFD might also
inhibit the resolution of inflammation as a result of a lack of certain crucial fatty acids.
Moreover, HFD-fed, as well LPS-challenged mice, displayed significant increases in several
long-chain acylcarnitines species and significant decreases in free carnitine and its metabolic precursor
deoxycarnitine. Notable increases were also apparent in several dicarboxylic acid species, oxidized lipid
intermediates generated via theω-oxidation pathway. The increase in these metabolites is consistent
with impairments in fatty acid oxidation, or alternatively, overwhelmed β-oxidation. It has been
described that during periods of fasting, increased lipolysis and oxidation of fatty acids in mitochondria
provides most of the energy needed. Fatty acids enter the cytosol from plasma and are transferred
into the mitochondria via the palmitoyl-CoA carnitine transferase II shuttle. This import requires
carnitine, which is associated with a decline in plasma carnitine levels [63,64]. In contrast, under obese
conditions spillover of acetyl- and acyl-CoA due to overwhelmed β-oxidation is buffered by releasing
the respective carnitines into plasma [17]. In the context of sepsis, accumulation of acylcarnitines has
been linked to dysfunctional β-oxidation [34]. The superinduction of acylcarnitines and dicarboxylic
acids observed in HFD-fed mice upon LPS treatment is consistent with further deterioration of systemic
fatty acid oxidation [28].
Furthermore, endocannabinoids were among the most dynamically altered metabolites in the
HFD_LPS- compared to the CD_LPS-treated group. Endocannabinoids and endocannabinoidome
mediators are derived from long-chain fatty acids, and it is therefore predictable that diets rich in
certain fatty acids are able to modulate tissue concentrations of the endocannabinoids. Obesity has
been linked to higher endocannabinoid plasma and adipose tissue levels, and altered expression of the
cannabinoid receptor 1 (CB1R). In adipose tissue, CB1R-mediated signaling has been shown to increase
lipogenesis and reduce mitochondrial biogenesis [65–68]. In the liver, HFD-increased endocannabinoid
levels and CB1R signaling contributed to increased fatty acid production. Genetic and pharmacological
blocking of the CB1R was shown to protect against the development of obesity, hepatic steatosis and
related inflammation [69,70]. Indeed, several lines of evidence support a role for endocannabinoids
in modulating obesity-induced inflammation in adipose tissue. A study by the Roche group has
demonstrated that inhibiting CB1R function attenuates LPS-induced TNFα and IL-6 expression in
human adipocytes [71].
To sum up, cells in different tissue niches and the body’s organs have a constant supply of
nutritional metabolites, which are required to keep cellular metabolism and function, and systemic
homeostasis. A disturbed supply of certain metabolites, due to altered eating habits, leads to
systemic immuno-metabolic imbalances, which derange cellular signaling on certain levels. Long-term,
diet-related perturbations, associated with intestinal dysbiosis and altered immune-metabolic signaling,
lead to pathophysiological conditions. In this study, we demonstrated the rapid and robust impact of
HFD feeding, as well as LPS challenge, on systemic metabolism. Four weeks of dietary intervention
profoundly induced systemic metabolic rewiring, which is reflected in the altered abundance of certain
lipoproteins, amino acids, as well as immuno-metabolites. In the long run, it will be of interest to study
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the effects of metabolic changes on immune cell reprogramming, altered inflammatory responses and
associated metabolic disease outcomes.
4. Materials and Methods
4.1. Mice
The Institutional Animal Care and Use Committees of the University of Massachusetts Medical
School approved the experiments performed according to local ethics regulations (IACUC 1945,
UMass Medical School, Worcester, MA, USA) and NIH guidelines. Ldlr−/− were initially purchased
from The Jackson Laboratory and kept in house. All mice have been previously backcrossed over ten
generations to the C57Bl6/J background. For all in vivo animal studies (Hifg fat diet feeding studies,
LPS challenge) age (8 weeks of age) and sex-matched female wild type, Ldlr−/− mice were used with
five mice per genotype. During experimental settings, mice had ad libitum access to food and water,
and were housed under a 12-h light-dark cycle.
4.2. Mouse In Vivo Studies
To induce hyperlipidemia and hypercholesterolemia, female mice were fed a high-fat diet (HFD;
Teklad 88137) consisting of 17.3% protein, 21.2% fat (saturated fat 12.8%, monounsaturated fat 5.6%,
polyunsaturated fat 1%) and 48.5% carbohydrates for four weeks. Chow diet (Prolab Isopro RMH 30;
LabDiet) consisted of 25% protein, 14% fat (ether extract) and 60% carbohydrates. To study long-term
diet effects on systemic metabolism, female mice were fed a HFD for four weeks, and subsequently
subjected to regular chow diet for additional four weeks (HFD > CD). To study additional effects of LPS
priming, mice received an intravenous injection of PBS (vehicle control) or E. coli-derived ultrapure
LPS (0111:B4; 10 µg/mouse) six hours before sacrifice. Blood was collected via cardiac puncture into
ethylene-diamine-tetraacetate (EDTA)-lined tubes and immediately placed on ice. After centrifugation
at 300× g for 10 min, serum was collected from supernatants. Samples were snap-frozen and kept at
−80 ◦C until analysis.
4.3. Metabolomic Analysis
The non-targeted metabolomic analysis of serum samples was performed by Metabolon,
Inc. (Durham, NC, USA), on a platform consisting of four independent ultrahigh performance
liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) methods. Serum samples were
extracted with methanol and analyzed as described. Briefly, a Waters ACQUITY ultra-performance
liquid chromatography (UPLC) and a Thermo Scientific Q-Exactive (Waltham, MA, USA) high
resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II)
source and Orbitrap mass analyzer (operated at 35,000 mass resolution were utilized for all methods.
Sample extracts were dried, then reconstituted in solvents compatible to each of the four methods.
Each reconstitution solvent contained a series of standards at fixed concentrations to ensure injection
and chromatographic consistency. One aliquot was analyzed using acidic positive ion conditions and
chromatographically optimized for more hydrophilic compounds. In this method, the extract was
gradient eluted from a C18 column (Waters UPLC BEH C18–2.1 × 100 mm, 1.7 µm, Milford, MA, USA)
using water and methanol, containing 0.05% perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA).
Another aliquot was analyzed using acidic positive ion conditions; however, it was chromatographically
optimized for more hydrophobic compounds. In this method, the extract was gradient eluted from the
same aforementioned C18 column using methanol, acetonitrile, water, 0.05% PFPA, and 0.01% FA and
was operated at an overall higher organic content. Another aliquot was analyzed using basic negative
ion optimized conditions using a separate dedicated C18 column. The basic extracts were gradient
eluted from the column using methanol and water, however with 6.5 mM Ammonium Bicarbonate
at pH 8. The fourth aliquot was analyzed via negative ionization following elution from a HILIC
column (Waters UPLC BEH Amide 2.1 × 150 mm, 1.7 µm) using a gradient consisting of water and
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acetonitrile with 10 mM Ammonium Formate, pH 10.8. The MS analysis alternated between MS
and data-dependent MSn scans using dynamic exclusion. The scan range varied slightly between
methods, but covered 70–1000 m/z. Raw data were extracted, peak-identified, and QC processed using
Metabolon’s hardware and software. Compounds were identified by comparison to library entries of
purified standards or recurrent unknown entities comprising retention time/index (RI), mass to charge
ratio (m/z), and chromatographic data (including MS/MS spectral data). Compound assignments were
done based on retention index within a narrow RI window of the proposed identification, accurate mass
match to the library +/− 10 ppm, and the MS/MS forward and reverse scores between the experimental
data and authentic standards. Metabolite abundances were determined by area-under-the-curve
quantification of respective peaks.
4.4. Statistical Analysis
Analysis of normalized metabolite abundances was performed using Microsoft Excel, GraphPad
Prism6 (San Diego, CA, USA) and MetaboAnalyst 4.0 [72]. Principle component analysis (PCA) was
performed using MetaboAnalyst to detect outliers. Outliers were verified using GraphPad Prism,
which led to the exclusion of four metabolites. To analyze significantly altered metabolites between
groups, multiple t-tests were performed, followed by false discovery rate (FDR) adjustment of p-values.
FDR-adjusted p-values (q-value) of 0.05 or smaller were considered significant. Pearson was performed
using MetaboAnalyst 4.0. Hierarchical clustering was performed using Clustvis [73]. For Volcano plot
data representation, normalized metabolite data were log-transformed. Heatmaps were generated
using Microsoft Excel and Clustvis. Venn diagrams were generated using InteractiVenn [74].
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regulated metabolites upon LPS challenge, upon diet intervention, and upon synergistic LPS and diet treatment.
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41. Cândido, F.G.; Valente, F.X.; Grześkowiak, Ł.M.; Moreira, A.P.B.; Rocha, D.M.U.P.; Alfenas, R.D.C.G. Impact
of dietary fat on gut microbiota and low-grade systemic inflammation: Mechanisms and clinical implications
on obesity. Int. J. Food Sci. Nutr. 2018, 69, 125–143. [CrossRef] [PubMed]
42. Lone, J.B.; Koh, W.Y.; Parray, H.A.; Paek, W.K.; Lim, J.; Rather, I.A.; Jan, A.T. Gut microbiome: Microflora
association with obesity and obesity-related comorbidities. Microb. Pathog. 2018, 124, 266–271. [CrossRef]
[PubMed]
43. Canfora, E.E.; Meex, R.C.R.; Venema, K.; Blaak, E.E. Gut microbial metabolites in obesity, NAFLD and T2DM.
Nat. Rev. Endocrinol. 2019, 15, 261–273. [CrossRef]
44. Cao, W.; Chin, Y.; Chen, X.; Mi, Y.; Xue, C.; Wang, Y.; Tang, Q. The role of gut microbiota in the resistance to
obesity in mice fed a high fat diet. Int. J. Food Sci. Nutr. 2020, 71, 453–463. [CrossRef]
45. Van Teijlingen Bakker, N.; Pearce, E.J. Cell-intrinsic metabolic regulation of mononuclear phagocyte activation:
Findings from the tip of the iceberg. Immunol. Rev. 2020, 295, 54–67. [CrossRef] [PubMed]
46. Abbott, S.K.; Else, P.L.; Atkins, T.A.; Hulbert, A.J. Fatty acid composition of membrane bilayers: Importance
of diet polyunsaturated fat balance. BBA Biomembr. 2012, 1818, 1309–1317. [CrossRef]
47. Lancaster, G.I.; Langley, K.G.; Berglund, N.A.; Kammoun, H.L.; Reibe, S.; Estevez, E.; Weir, J.; Mellett, N.A.;
Pernes, G.; Conway, J.R.W.; et al. Evidence that TLR4 is not a Receptor for Saturated Fatty Acids but Mediates
Lipid-Induced Inflammation by Reprogramming Macrophage Metabolism. Cell Metab. 2018, 27, 1096–1110.
[CrossRef]
Metabolites 2020, 10, 336 19 of 20
48. Köberlin, M.S.; Snijder, B.; Heinz, L.X.; Baumann, C.L.; Fauster, A.; Vladimer, G.I.; Gavin, A.-C.;
Superti-Furga, G. A Conserved Circular Network of Coregulated Lipids Modulates Innate Immune Responses.
Cell 2015, 162, 170–183. [CrossRef]
49. Rong, X.; Albert, C.J.; Hong, C.; Duerr, M.A.; Chamberlain, B.T.; Tarling, E.J.; Ito, A.; Gao, J.; Wang, B.;
Edwards, P.A.; et al. LXRs Regulate ER Stress and Inflammation through Dynamic Modulation of Membrane
Phospholipid Composition. Cell Metab. 2013, 18, 685–697. [CrossRef]
50. Listenberger, L.L.; Han, X.; Lewis, S.E.; Cases, S.; Farese, R.V.; Ory, D.S.; Schaffer, J.E. Triglyceride accumulation
protects against fatty acid-induced lipotoxicity. Proc. Natl. Acad. Sci. USA 2003, 100, 3077–3082. [CrossRef]
51. Erbay, E.; Babaev, V.R.; Mayers, J.R.; Makowski, L.; Charles, K.N.; Snitow, M.E.; Fazio, S.; Wiest, M.M.;
Watkins, S.M.; Linton, M.F.; et al. Reducing endoplasmic reticulum stress through a macrophage lipid
chaperone alleviates atherosclerosis. Nat. Med. 2009, 15, 1383–1391. [CrossRef] [PubMed]
52. Rial, E.; Rodríguez-Sánchez, L.; Gallardo-Vara, E.; Zaragoza, P.; Moyano, E.; González-Barroso, M.M.
Lipotoxicity, fatty acid uncoupling and mitochondrial carrier function. BBA Bioenerg. 2010, 1797, 800–806.
[CrossRef]
53. Schönfeld, P.; Wojtczak, L. Short- and medium-chain fatty acids in energy metabolism: The cellular perspective.
J. Lipid Res. 2016, 57, 943–954. [CrossRef]
54. Thiele, C.; Papan, D.; Hoelper, D.; Kusserow, K.; Gaebler, A.; Schoene, M.; Piotrowitz, K.; Lohmann, D.;
Spandl, J.; Stevanovic, A.; et al. Tracing Fatty Acid Metabolism by Click Chemistry. ACS Chem. Biol. 2012, 7,
2004–2011. [CrossRef]
55. Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; Yamada, M.; Sugimoto, Y.; Miyazaki, S.;
Tsujimoto, G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat.
Med. 2004, 11, 90–94. [CrossRef] [PubMed]
56. Lu, X.; Zhao, X.; Feng, J.; Liou, A.P.; Anthony, S.; Pechhold, S.; Sun, Y.; Lu, H.; Wank, S. Postprandial inhibition
of gastric ghrelin secretion by long-chain fatty acid through GPR120 in isolated gastric ghrelin cells and mice.
Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303, G367–G376. [CrossRef] [PubMed]
57. Oh, D.Y.; Talukdar, S.; Bae, E.J.; Imamura, T.; Morinaga, H.; Fan, W.; Li, P.; Lu, W.J.; Watkins, S.M.; Olefsky, J.M.
GPR120 is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-Inflammatory and Insulin-Sensitizing
Effects. Cell 2010, 142, 687–698. [CrossRef]
58. Zhao, C.; Zhou, J.; Meng, Y.; Shi, N.; Wang, X.; Zhou, M.; Li, G.; Yang, Y. DHA Sensor GPR120 in Host
Defense Exhibits the Dual Characteristics of Regulating Dendritic Cell Function and Skewing the Balance of
Th17/Tregs. Int. J. Biol. Sci. 2019, 16, 374–387. [CrossRef]
59. Matsumoto, M.; Sata, M.; Fukuda, D.; Tanaka, K.; Soma, M.; Hirata, Y.; Nagai, R. Orally administered
eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice. Atherosclerosis
2008, 197, 524–533. [CrossRef]
60. Serhan, C.N.; Levy, B.D. Resolvins in inflammation: Emergence of the pro-resolving superfamily of mediators.
J. Clin. Investig. 2018, 128, 2657–2669. [CrossRef]
61. Kasikara, C.; Doran, A.C.; Cai, B.; Tabas, I. The role of non-resolving inflammation in atherosclerosis. J. Clin.
Investig. 2018, 128, 2713–2723. [CrossRef] [PubMed]
62. Ishihara, T.; Yoshida, M.; Arita, M. Omega-3 fatty acid-derived mediators that control inflammation and
tissue homeostasis. Int. Immunol. 2019, 31, 559–567. [CrossRef] [PubMed]
63. Bartlett, K.; Eaton, S. Mitochondrial beta-oxidation. Eur. J. Biochem. 2004, 271, 462–469. [CrossRef]
64. Eaton, S. Control of mitochondrial beta-oxidation flux. Prog. Lipid Res. 2002, 41, 197–239. [CrossRef]
65. Izzo, A.A.; Piscitelli, F.; Capasso, R.; Aviello, G.; Romano, B.; Borrelli, F.; Petrosino, S.; di Marzo, V. Peripheral
endocannabinoid dysregulation in obesity: Relation to intestinal motility and energy processing induced by
food deprivation and re-feeding. Br. J. Pharmacol. 2009, 158, 451–461. [CrossRef]
66. Di Marzo, V. Targeting the endocannabinoid system: To enhance or reduce? Nat. Rev. Drug Discov. 2008, 7,
438–455. [CrossRef]
67. Teixeira, D.; Pestana, D.; Faria, A.; Calhau, C.; Azevedo, I.; Monteiro, R. Modulation of adipocyte biology by
δ(9)-tetrahydrocannabinol. Obesity 2010, 18, 2077–2085. [CrossRef]
68. Tedesco, L.; Valerio, A.; Dossena, M.; Cardile, A.; Ragni, M.; Pagano, C.; Pagotto, U.; Carruba, M.O.; Vettor, R.;
Nisoli, E. Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose
tissue, muscle, and liver: The role of eNOS, p38 MAPK, and AMPK pathways. Diabetes 2010, 59, 2826–2836.
[CrossRef]
Metabolites 2020, 10, 336 20 of 20
69. DeLeve, L.D.; Wang, X.; Kanel, G.C.; Atkinson, R.D.; McCuskey, R.S. Prevention of hepatic fibrosis in a
murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am. J. Pathol. 2008, 173, 993–1001.
[CrossRef]
70. Gary-Bobo, M.; Elachouri, G.; Scatton, B.; Le Fur, G.; Oury-Donat, F.; Bensaid, M. The cannabinoid CB1
receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte
maturation in cultured mouse 3T3 F442A preadipocytes. Mol. Pharmacol. 2006, 69, 471–478. [CrossRef]
71. Murumalla, R.; Bencharif, K.; Gence, L.; Bhattacharya, A.; Tallet, F.; Gonthier, M.-P.; Petrosino, S.; di Marzo, V.;
Cesari, M.; Hoareau, L.; et al. Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human
adipocyte inflammatory profile and differentiation. J. Inflamm. 2011, 8, 33. [CrossRef] [PubMed]
72. Chong, J.; Wishart, D.S.; Xia, J. Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics
Data Analysis. Curr. Protoc. Bioinform. 2019, 68, e86. [CrossRef]
73. Metsalu, T.; Vilo, J. ClustVis: A web tool for visualizing clustering of multivariate data using Principal
Component Analysis and heatmap. Nucleic Acids Res. 2015, 43, W566–W570. [CrossRef] [PubMed]
74. Heberle, H.; Meirelles, G.V.; da Silva, F.R.; Telles, G.P.; Minghim, R. InteractiVenn: A web-based tool for the
analysis of sets through Venn diagrams. BMC Bioinform. 2015, 16, 213–217. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
